Comparison of the Effect of Lipophilic and Hydrophilic Statins on Serum Adiponectin Levels in Patients with Mild Hypertension and Dyslipidemia: Kinki Adiponectin Interventional (KAI) Study

References

• Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24: 29–33
   PubMed Web of Science ®Google Scholar
• Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K. Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res. 2003; 26: 705–710
   PubMed Web of Science ®Google Scholar
• Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, Kawano Y, Funahashi T, Ogihara T. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006; 98: 1603–1608
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Higashiura K, Miyazaki Y, Murakami H, Hyakukoku M, Shimamoto K. Low adiponectin level in young normotensive men with a family history of essential hypertension. Hypertens Res. 2005; 28: 141–146
   PubMed Web of Science ®Google Scholar
• Behre CJ, Gummesson A, Jernås M, Lystig TC, Fagerberg B, Carlsson B, Carlsson LM. Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism. 2007; 56: 1022–1028
   PubMed Web of Science ®Google Scholar
• Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Murakami K, Higaki J. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther. 2006; 28: 1677–1685
   PubMed Web of Science ®Google Scholar
• Thomas EL, Potter E, Tosi I, Fitzpatrick J, Hamilton G, Amber V, Hughes R, North C, Holvoet P, Seed M, Betteridge DJ, Bell JD, Naoumova RP. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: Relation to liver, muscle and regional body fat content. Atherosclerosis. 2007; 195: e181–e190
   PubMedGoogle Scholar
• Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007; 30: 387–394
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, Sakamoto T, Horibata Y, Watanabe K, Koga H, Sugamura K, Otsuka F, Shimomura I, Ogawa H. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis. 2007; 194: e43–e51
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Sakamoto T, Ogawa H. for the Kumamoto Joint Research on Hypercholesterolemia (KOJIROU) Investigators. The effect of six months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: A pilot study. Clin Ther. 2006; 28: 1012–1021
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005; 45: 1649–1653
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004; 110: 3687–3692, YH
   PubMed Web of Science ®Google Scholar
• Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control. Diabetologia. 2006; 49: 1881–1892
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003; 92: 152–160
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461–470
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Nitta K, Yamaagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007; 50: 927–937
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACLE study. A randomized controlled trial. JAMA., 2001;285:1711–1718
   Google Scholar
• Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ I, II, Jones PH, West MS, Gould KL, Gotto AM, Jr. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997; 80: 278–286
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301–1307
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE). A randomized trial and cohort study. JAMA. 2001; 286: 64–70
   PubMed Web of Science ®Google Scholar
• Abe K, Nakayama M, Yoshimura M, Nakamura S, Ito T, Yamamuro M, Sakamoto T, Miyamoto Y, Yoshimasa Y, Saito Y, Nakao K, Yasue H, Ogawa H. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: A relation with the −786T>C polymorphism. Pharmacogenet Genomics. 2005; 15: 329–336
   PubMed Web of Science ®Google Scholar
• Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, Kihara S, Caslake MJ, McMahon A, Shepherd J, Funahashi T, Shimomura I. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis. 2008; 196: 114–121
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundan Clin Paharmacol. 2005; 19: 117–125
   PubMed Web of Science ®Google Scholar
• Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277: 25863–25866
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and Apo E-deficient mice from atherosclerosis. J Biol Chem. 2003; 278: 2461–2468
   PubMed Web of Science ®Google Scholar
• Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004; 109: 2046–2049
   PubMed Web of Science ®Google Scholar
• Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001; 34: 583–588
   PubMed Web of Science ®Google Scholar
• Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction of sudden death in patients with angina pectoris. Europian Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995; 332: 635–641
   PubMed Web of Science ®Google Scholar
• Wang HY, Gao PJ, Ji KD, Shen WF, Fan CL, Lu L, Zhu DL. Circulating endothelial progenitor cells, C-reactive protein and severity of coronary stenosis in Chinese patients with coronary artery disease. Hypertens Res. 2007; 30: 133–141
   PubMed Web of Science ®Google Scholar
• Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992; 4: 361–368
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165–2168
   PubMed Web of Science ®Google Scholar
• Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation. 2001; 103: 1194–1197
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20–28
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671–674
   PubMed Web of Science ®Google Scholar
• Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: Its origin and pathophysiological significance. Am J Pathol. 2005; 167: 1139–1148
   PubMed Web of Science ®Google Scholar
• Devaj S, Chan E, Jialal I. Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006; 91: 4489–4496
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Preffer MA, Sacks F, Braunwald E. for the Cholesterol and Recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999; 100: 230–235
   PubMed Web of Science ®Google Scholar
• Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995; 26: 670–675
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Aleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet. 2003; 361: 2005–2016
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005; 112: 171–178
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004; 57: 728–734
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK. for the Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol. 2007; 2: 1131–1139
   PubMed Web of Science ®Google Scholar
• O'Donnell MP, Kasiske BL, Kim Y, et al. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis. 1993; 22: 83–89
   PubMed Web of Science ®Google Scholar
• Yokota N, O'Donnell MP, Daniels F, Burne-Taney M, Keane WF, Kasiske BL, Rabb H. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol. 2003; 23: 13–17
   PubMed Web of Science ®Google Scholar
• Massy ZA, Kim Y, Guiijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human masangial cell inflammation: Effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000; 267: 536–540
   PubMed Web of Science ®Google Scholar
• Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res. 2001; 101: 79–84
   PubMed Web of Science ®Google Scholar
• Yamashita T, Kawashima S, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M. A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens. 2002; 20: 2465–2473
   PubMed Web of Science ®Google Scholar
• Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I, Ito T, Funahashi T. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Atheroscler Thromb Vasc Biol. 2007; 27: 1910–1917
   PubMed Web of Science ®Google Scholar
• Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383–1389
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685–696
   PubMed Web of Science ®Google Scholar
• West of Scotland Coronary Prevention Study Group. Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 97: 1440–1445
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet. 2006; 368: 1155–1163
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A. MUSASHI-AMI Investigators. Usefulness of hydrophilic vs. lipophilic statins after acute myocardial infarction. Subanalysis of MUSASHI-AMI. Circ J. 2007; 71: 1348–1353
   PubMed Web of Science ®Google Scholar
• Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet. 2002; 359: 2195–2198
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98: 2088–2093
   PubMed Web of Science ®Google Scholar
• Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, Shinomiya K, Kosaka H, Kohno M. Differential impact of atorvastatin vs. pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J. 2007; 71: 144–152
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495–1504
   PubMed Web of Science ®Google Scholar
• Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM, Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006; 48: 1793–1799
   PubMed Web of Science ®Google Scholar
• Ford I, Murray H, Packerd CJ, Shepherd J, Macfariane PW, Cobbe SM. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007; 357: 1477–1486
   PubMed Web of Science ®Google Scholar